Xeris Biopharma Holdings, Inc. (NASDAQ: XERS)

$6.26 ▲ +0.12 (+1.87%)

As of May 12, 2026 12:12 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001867096

Market Cap 982.60 Mn

P/E 1,773.65

P/S 3.37

Div. Yield 0.00

Total Debt (Qtr) 220.34 Mn

Revenue Growth (1y) (Qtr) 42.78

Add ratio to table...

About

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. The company offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis. Xeris is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous levothyroxine formulation...

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. The company offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis. Xeris is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous levothyroxine formulation leveraging its proprietary XeriSol technology.

Xeris generates revenue through the sale of its three commercial products: Recorlev, Gvoke, and Keveyis. Recorlev is a cortisol synthesis inhibitor approved for adults with Cushing's syndrome for whom surgery is not an option or has not been curative. Gvoke is a ready-to-use, liquid-stable glucagon product indicated for pediatric and adult patients with diabetes aged two years and above for the treatment of severe hypoglycemia. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis, a rare genetic neuromuscular disorder. The company serves patients through prescriptions written by healthcare providers and distributed via specialty pharmacies.

The company operates through the following segments:

• Recorlev segment includes the development and commercialization of Recorlev for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome.

• Gvoke segment includes the development and commercialization of Gvoke for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.

• Keveyis segment includes the development and commercialization of Keveyis for the treatment of Primary Periodic Paralysis.

• XP-8121 segment includes the development of once-weekly subcutaneous levothyroxine for the treatment of hypothyroidism, leveraging the proprietary XeriSol technology.

Xeris holds a differentiated position in the endocrine and rare disease therapeutic areas through its portfolio of commercial products and proprietary formulation technologies. The company competes with established pharmaceutical and specialty pharmaceutical companies in each of its therapeutic areas, including Corcept Therapeutics and Recordati for Cushing’s syndrome therapies, Amphastar and Zealand Pharma for ready-to-use glucagon products, and various generic manufacturers for Keveyis. Xeris leverages its proprietary non-aqueous XeriSol and XeriJect formulation technologies to create ready-to-use, room-temperature stable injectable formulations, providing a competitive advantage in drug delivery and patient convenience. The company’s intellectual property portfolio, including patents extending to 2040 for Recorlev and 2036 for Gvoke, supports its market position.

Xeris serves patients diagnosed with chronic endocrine and neurological conditions in the United States. The company’s customer base includes individuals with Cushing’s syndrome requiring pharmacologic intervention, patients with diabetes at risk of severe hypoglycemia, and individuals living with Primary Periodic Paralysis. Additionally, Xeris targets patients with hypothyroidism for its pipeline product XP-8121. The company collaborates with healthcare providers, specialty pharmacies, and third-party payors to ensure patient access to its therapies.

Investment thesis

Bull case

The company’s revenue trajectory, driven by a 40% YoY jump in total product revenue, demonstrates that the core therapeutic area—endogenous Cushing’s syndrome—has not yet reached saturation. Recorlev’s patient base grew by 108% in Q3, suggesting a steady stream of new diagnoses that can be captured by an expanding commercial footprint. Management’s plan to nearly double the sales and patient support teams by mid‑2026 is positioned to sustain this growth momentum, with the company projecting a 42% increase in total revenue for 2025. This expansion, coupled with an 85% gross margin, indicates strong operational leverage that can absorb the incremental SG&A costs without eroding profitability.
XP‑8121, a once‑weekly subcutaneous formulation for primary hypothyroidism, is in Phase‑III readiness and slated for trial initiation in 2026. The product leverages XeriSol technology to deliver a patient‑friendly dosing schedule that could attract a sizeable market share in an industry dominated by daily oral levothyroxine. Early data from the American Thyroid Association meeting, where key opinion leaders expressed enthusiasm, suggests that the product has the potential to become a blockbuster. The combination of a novel delivery platform and a large patient population supports a high upside for the company’s long‑term pipeline value.
The company’s intellectual property strategy has yielded two recent Orange‑Book patents: one for Recorlev and a composition‑of‑matter patent for XP‑8121. These patents reinforce a durable competitive moat that protects the company from generic or biosimilar competition for the foreseeable future. The IP portfolio also enhances the company’s attractiveness as a strategic partner or acquisition target, thereby potentially unlocking additional upside for shareholders. Moreover, a strong patent position may provide pricing power, which is critical in the specialty drug space where reimbursement pressures are high.
Cash generation has been a consistent theme, with adjusted EBITDA reaching $17.4 million in Q3 and positive cash flow reported in every quarter. This financial discipline suggests that the company can fund both commercial expansion and pipeline development without the immediate need for external financing. In addition, a robust balance sheet provides a cushion to navigate the uncertainties that accompany pipeline milestones, such as regulatory delays or unexpected clinical setbacks. The ability to self‑fund growth reduces dilution risk and preserves shareholder value over the medium term.
Recorlev’s patient retention metrics appear stable, with no significant discontinuation signals reported during the Q3 call. The company’s emphasis on holistic patient support—encompassing education, monitoring, and adherence programs—contributes to the durability of its franchise. This patient‑centric approach is likely to translate into repeat prescriptions and a predictable revenue stream, further underpinning the company’s financial resilience. Such a support ecosystem also differentiates Xeris from competitors that may offer similar therapies without robust post‑prescription engagement.

The company’s revenue trajectory, driven by a 40% YoY jump in total product revenue, demonstrates that the core therapeutic area—endogenous Cushing’s syndrome—has not yet reached saturation. Recorlev’s patient base grew by 108% in Q3, suggesting a steady stream of new diagnoses that can be captured by an expanding commercial footprint. Management’s plan to nearly double the sales and patient support teams by mid‑2026 is positioned to sustain this growth momentum, with the company projecting a 42% increase in total revenue for 2025. This expansion, coupled with an 85% gross margin, indicates strong operational leverage that can absorb the incremental SG&A costs without eroding profitability.
XP‑8121, a once‑weekly subcutaneous formulation for primary hypothyroidism, is in Phase‑III readiness and slated for trial initiation in 2026. The product leverages XeriSol technology to deliver a patient‑friendly dosing schedule that could attract a sizeable market share in an industry dominated by daily oral levothyroxine. Early data from the American Thyroid Association meeting, where key opinion leaders expressed enthusiasm, suggests that the product has the potential to become a blockbuster. The combination of a novel delivery platform and a large patient population supports a high upside for the company’s long‑term pipeline value.
The company’s intellectual property strategy has yielded two recent Orange‑Book patents: one for Recorlev and a composition‑of‑matter patent for XP‑8121. These patents reinforce a durable competitive moat that protects the company from generic or biosimilar competition for the foreseeable future. The IP portfolio also enhances the company’s attractiveness as a strategic partner or acquisition target, thereby potentially unlocking additional upside for shareholders. Moreover, a strong patent position may provide pricing power, which is critical in the specialty drug space where reimbursement pressures are high.
Cash generation has been a consistent theme, with adjusted EBITDA reaching $17.4 million in Q3 and positive cash flow reported in every quarter. This financial discipline suggests that the company can fund both commercial expansion and pipeline development without the immediate need for external financing. In addition, a robust balance sheet provides a cushion to navigate the uncertainties that accompany pipeline milestones, such as regulatory delays or unexpected clinical setbacks. The ability to self‑fund growth reduces dilution risk and preserves shareholder value over the medium term.
Recorlev’s patient retention metrics appear stable, with no significant discontinuation signals reported during the Q3 call. The company’s emphasis on holistic patient support—encompassing education, monitoring, and adherence programs—contributes to the durability of its franchise. This patient‑centric approach is likely to translate into repeat prescriptions and a predictable revenue stream, further underpinning the company’s financial resilience. Such a support ecosystem also differentiates Xeris from competitors that may offer similar therapies without robust post‑prescription engagement.

Bear case

Despite Q3 gains, the company’s heavy reliance on Recorlev for over half of total revenue exposes it to concentration risk. A decline in patient access due to reimbursement changes, insurance coverage restrictions, or payer negotiations could disproportionately affect the top line. The drug’s specialty nature also subjects it to heightened scrutiny from payers seeking value‑based pricing, potentially leading to price compression. These dynamics create a scenario where a single product’s underperformance could materially degrade the company’s profitability.
The salesforce expansion, while potentially revenue‑generating, also introduces significant cost pressure that could offset the incremental revenue gains. The company’s SG&A expense is already trending upward, and the near‑doubling of the sales team may not yield proportionate sales growth if market penetration slows or if competitors intensify their own sales initiatives. Moreover, the ramp‑up period for new reps typically spans several quarters, implying a lag between investment and return that could strain cash flow in the short term.
Recorlev’s growth has been described as a “billion‑dollar product” trajectory, yet the company has not disclosed explicit market size estimates or competitive benchmarks. Without transparent data, the optimistic forecast may overstate realistic upside, leading to overvaluation. Historical patient growth may plateau as the market matures, and any unforeseen medical or regulatory developments could dampen demand. This lack of clarity introduces substantial uncertainty into the company’s revenue projections.
The pipeline’s XP‑8121, while innovative, carries typical clinical development risks. Phase‑III trials are expensive and have a high failure rate, and any safety or efficacy concerns could delay or derail the program. The company’s reliance on the platform technology means that a single failure could erode confidence in its broader technology strategy. Moreover, the need for extensive device validation could encounter unforeseen regulatory hurdles, extending timelines and increasing costs.
The company’s IP portfolio, though robust, may face challenges from generic competitors as patents expire or are invalidated. In specialty drug markets, generic entry can occur swiftly once exclusivity lapses, eroding margins. The company has not provided a clear strategy for post‑patent protection, such as formulation changes or new indications, leaving it vulnerable to a loss of exclusivity. This potential erosion could have a material impact on long‑term profitability.

Despite Q3 gains, the company’s heavy reliance on Recorlev for over half of total revenue exposes it to concentration risk. A decline in patient access due to reimbursement changes, insurance coverage restrictions, or payer negotiations could disproportionately affect the top line. The drug’s specialty nature also subjects it to heightened scrutiny from payers seeking value‑based pricing, potentially leading to price compression. These dynamics create a scenario where a single product’s underperformance could materially degrade the company’s profitability.
The salesforce expansion, while potentially revenue‑generating, also introduces significant cost pressure that could offset the incremental revenue gains. The company’s SG&A expense is already trending upward, and the near‑doubling of the sales team may not yield proportionate sales growth if market penetration slows or if competitors intensify their own sales initiatives. Moreover, the ramp‑up period for new reps typically spans several quarters, implying a lag between investment and return that could strain cash flow in the short term.
Recorlev’s growth has been described as a “billion‑dollar product” trajectory, yet the company has not disclosed explicit market size estimates or competitive benchmarks. Without transparent data, the optimistic forecast may overstate realistic upside, leading to overvaluation. Historical patient growth may plateau as the market matures, and any unforeseen medical or regulatory developments could dampen demand. This lack of clarity introduces substantial uncertainty into the company’s revenue projections.
The pipeline’s XP‑8121, while innovative, carries typical clinical development risks. Phase‑III trials are expensive and have a high failure rate, and any safety or efficacy concerns could delay or derail the program. The company’s reliance on the platform technology means that a single failure could erode confidence in its broader technology strategy. Moreover, the need for extensive device validation could encounter unforeseen regulatory hurdles, extending timelines and increasing costs.
The company’s IP portfolio, though robust, may face challenges from generic competitors as patents expire or are invalidated. In specialty drug markets, generic entry can occur swiftly once exclusivity lapses, eroding margins. The company has not provided a clear strategy for post‑patent protection, such as formulation changes or new indications, leaving it vulnerable to a loss of exclusivity. This potential erosion could have a material impact on long‑term profitability.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools